KRTAP9-8: A Potential Drug Target and Biomarker (G83901)

Target Name: KRTAP9-8

NCBI ID: G83901

KRTAP9-8

KRTAP9-8: A Potential Drug Target and Biomarker

KRTAP9-8, also known as KAP9.8, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is Kallikrein-related protein 9.8, and it is a member of the kallikrein family of proteins. KRTAP9-8 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

The kallikrein family of proteins plays a crucial role in the regulation of various physiological processes in the body, including blood clotting, inflammation, and stress responses. KRTAP9-8 is involved in these processes as well, and its function in the regulation of blood clots has been extensively studied.

Blood clots are a serious condition that can cause stroke, heart attack, and other complications. According to the World Health Organization (WHO), approximately 170 million people worldwide die each year due to blood clots, making it the leading cause of morbidity and mortality.

KRTAP9-8 has been shown to play a role in the regulation of blood clots. Several studies have shown that KRTAP9-8 can inhibit the aggregation of platelet cells, which are a key component of blood clots. This means that KRTAP9-8 can potentially be used as a drug target to prevent blood clots from forming.

In addition to its potential use as a blood clot drug target, KRTAP9-8 has also been shown to be a potential biomarker for various diseases. For example, some studies have shown that KRTAP9-8 levels can be used as a diagnostic marker for cancer, particularly ovarian cancer. This is because KRTAP9-8 is often overexpressed in cancer cells, and its levels can be used as a marker for the presence of cancer.

Another study has shown that KRTAP9-8 levels can be used as a biomarker for neurodegenerative disorders, such as Alzheimer's disease. This is because KRTAP9-8 is often overexpressed in neurodegenerative disorder cells, and its levels can be used as a marker for the presence of these disorders.

In addition to its potential use as a drug target and biomarker, KRTAP9-8 has also been shown to have potential therapeutic benefits. For example, some studies have shown that inhibiting KRTAP9-8 can protect against neurodegenerative disorders, such as Alzheimer's disease. This is because KRTAP9-8 is involved in the regulation of neurodegenerative disorder-related inflammation, and its inhibition can potentially reduce inflammation and protect against neurodegeneration.

Overall, KRTAP9-8 is a protein that has the potential to be a drug target and biomarker for various diseases. Further research is needed to fully understand its function and potential therapeutic benefits.

Protein Name: Keratin Associated Protein 9-8

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP9-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP9-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets